Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations
“This new patent signals Sermonix’s continued momentum toward the broader study of and potential use of lasofoxifene beyond that in the ESR1-mutated setting, including use in earlier lines of therapy in patients with wild-type (WT) ER,” said Dr. David Portman, Sermonix founder and chief executive officer. “There is great medical need for efficacious and well-tolerated new therapies for this large population of breast cancer patients with WT ER who recur in the adjuvant setting or progress in the advanced setting on aromatase inhibitors. We look forward to investigating lasofoxifene’s potential as an effective therapy option for all hormone-treatment resistant breast tumors.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.